The interaction of intestinal IgA responses with systemic IgG-mediated disease is a potentially important axis of therapeutic intervention, particularly in light of the new appreciation of the gut–adipose tissue axis of metabolic disease (149, 150). The gene discussed is CD79A; the disease is Other metabolic disease.